Luxembourg Parkinson’s Study: 1600 participants recruited!


In 2015, the ambitious National Centre of Excellence in Research on Parkinson’s Disease (NCER-PD) was launched with the support of the FNR. This research programme brings together research institutions focusing on Parkinson’s disease in Luxembourg, with the aim of answering urgent questions on Parkinson’s disease. As of the end of 2019, the Luxembourg Parkinson’s Study has reached its ambitious goal: 800 patients and 800 controls have been recruited in Luxembourg and the Greater Region.

A clinical team set out to recruit hundreds of patients and controls persons for the Luxembourg Parkinson’s Study, and researchers analysed the clinical data and samples collected.

Target reached

In Luxembourg, the number of people with Parkinson’s disease is estimated between 1000 and 1200. “Recruiting 800 patients out of 1200 was a bold objective that we set for ourselves. We are really proud to have reached our target. The whole NCER-PD team did an impressive job! It definitely is an important milestone for the Luxembourg Parkinson’s Study and biomedical research in Luxembourg”, says Prof. Rejko Krüger, coordinator of the NCER-PD.

This would not have been possible without the support of so many people that volunteered their time to participate in the study, all with their very own motivation to do so. Just like the 800th patient and the 800th healthy control who recently joined the study.

“I participated in the Luxembourg Parkinson’s Study in honour of one of my closest friends, who also suffers from Parkinson’s disease. While I am doing quite well since my diagnosis in 2015, his quality of life is severely affected,” says Mr. Pedersen. “We clearly need more research to find out why the disease differs so much from person to person and how to best treat it.”

Ms. Kaesz-Weber, the 800th healthy control, learnt about the Luxembourg Parkinson’s Study thanks to a visit of the labs at the Luxembourg Centre for Systems Biomedicine a few years ago. Afterwards, she mentioned it to one of her friends who has Parkinson’s disease. “My friend was treated at the CHL for three years. I joined her for some of the appointments and saw the neurological tests that were done. It made an impression on me! When we heard about the study again in the media, we were both very motivated to participate. I think it is something we all owe to do. It took us a while to make it happen but, in the end, I joined just in time to be the 800th control!”

Luxembourg Parkinson's Study - 800th control

As the project is now entering its second phase, the recruitment for this specific group will be slowing down, but follow-up examinations of existing participants will continue: yearly for patients and every four years for controls.

What’s next?

After receiving another 6 MEUR from the FNR in funding until 2023, the Luxembourg Parkinson’s Study team will establish an additional cohort, meaning a new group of participants,  focusing on the early signs of Parkinson’s disease. “For this cohort, we are looking for volunteers affected by a specific sleep disturbance called REM-Sleep Behaviour Disorder (RBD).”

RBD is characterised by acting out dreams in association with complex movements during a sleep phase called REM (sleep phase accompanied by rapid eye movements). This disorder can be treated when appropriately diagnosed.  It is of particular interest to the NCER-PD research team as people with RBD have a higher risk of developing neurodegenerative diseases such as Parkinson’s disease on the long run.

By closely examining people with RBD and conducting annual follow-ups, researcher want to investigate early signs of Parkinson’s disease, and look deeper into which factors play a role in its development. It is essential to understand the first signs and evolution in the early phase in order to identify novel disease-modifying treatment options (treatments either slowing down or stopping the neurodegenerative process), and to prevent Parkinson’s disease and neurodegenerative diseases in general.

To find other interviews of study participants, click on the links below:

This item was originally published on – image copyright:


FNR funds Luxembourg Parkinson’s Study with an additional 6 million euros

In spring 2015, the National Centre for Excellence in Research on Parkinson’s Disease (NCER-PD) was created as the very first inter-institutional research programme of its kind in Luxembourg. It represents a joint effort between five partners that unite their complementary expertise for Parkinson’s disease (PD). The Luxembourg National Research Fund (FNR) has committed 8.3 million euros to this collaborative research programme for the past four years. At the end of this first funding period, the programme has been evaluated with outstanding scores by an international jury of experts. This paved the way for its second phase until May 2023, funded with an additional 6 MEUR.

Launch of ParkinsonNet Luxembourg

The Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg and the Ministry of Health on 23 March 2018 announced the launch of ParkinsonNet – a network that will enable the exchange between Parkinson’s physicians, researchers and therapists, with the aim of improving the overall patient experience of people with Parkinson’s disease.

FNR, University of Luxembourg and LCSB leaders join Luxembourg Parkinson Study as healthy control subjects

Last week, the FNR’s Secretary General Dr Marc Schiltz volunteered as a control subject in the Luxembourg Parkinson Study, within the National Centre for Excellence in Research (NCER-PD), together with Prof Dr Rainer Klump, the President of the University of Luxembourg and Prof Dr Rudi Balling, the Director of the LCSB. This was done to … Continued

Participants Needed: Help advance Luxembourg’s major Parkinson’s research study!

The National Centre of Excellence in Research on Parkinson’s Disease (NCER-PD) is seeking participants to take part in a large research study in Luxembourg. Besides patients, the study is also particularly in need of healthy control subjects – members of the general public who are not affected by the disease – especially men over the … Continued

NCER-PD Newsletter now available!

The second of the bi-annual newsletter, created by the NCER-PD consortium to regularly brief all interested parties about the progress of the programme, is now available. Amongst other information, it contains an update from the large clinical cohort study, which forms the centre piece of the NCER-PD programme. The newsletter features an interview with Rudi … Continued

Donation from the André et Henriette Losch Foundation puts Parkinson’s research team on the road

Thanks to a generous donation from the André et Henriette Losch Foundation, in future it will be easier for Parkinson’s patients to participate in the Luxembourg Parkinson’s study. The study is part of the NCER programme, launched by the FNR in 2015. André Losch, Chairman of the foundation, handed the keys of the new “NCER-PD Flying … Continued

The first newsletter of the National Centre of Excellence in Research on Parkinson’s Disease is out!

In April 2015, the FNR launched a new initiative called the National Centre of Excellence in Research on Parkinson’s disease. For the first time, all national biomedical research actors join forces in a hitherto unique funding programme. One of their goals is to become an important player in international Parkinson’s disease research. Another is to … Continued

First Consortium Meeting of the National Centre of Excellence in Research on Parkinson’s disease (NCER-PD)

On Monday, 9 November 2015, the first formal consortium meeting of the National Centre of Excellence in Research on Parkinson’s disease (NCER-PD) took place at the Maison du Savoir in Esch-Belval. Around 50 representatives from all national and international partners gathered to exchange information about their plans and progress. Launched in April 2015, the Parkinson’s … Continued

Participants Needed: Be Part of Major Parkinson’s Research Study in Luxembourg

The National Centre of Excellence in Research (NCER) on Parkinson’s Disease is seeking participants to take part in a large research study in Luxembourg. The researchers leading the study hope to involve all Parkinson’s patients in the Luxembourg greater region, as well members of the general public who are not affected by the disease. The … Continued

Launch of National Centre of Excellence in Research in Parkinson’s Disease

NCER is a new multiannual programme funded by the FNR that aims to establish Luxembourg internationally as a centre of excellence in a particular research field. The first such programme, NCER-PD (National Centre of Excellence in Research on Parkinson’s disease), was approved for launch in 2015 and will focus on improving the early-stage diagnosis on … Continued

Related highlights

Spotlight on Young Researchers: Towards predicting ageing-related diseases

Spotlight on Young Researchers: The role a gene plays in neurodegeneration and cancer

Wastewater reveals clues about microorganisms, holds promise for future microbiome engineering

NCER-PD: Excellent results rewarded with a second funding period

What microbes really do in our guts

Genetic forms of Parkinson’s disease: Stem cell research offers new insights

Spotlight on Young Researchers: Nathasia Mudiwa Muwanigwa

Toward a better understanding and diagnosis of neurodegeneration and brain tumours

Microbiome research: unlocking basic unknowns in human health

Connecting fundamental research and clinical care

From flood prediction to deep brain stimulation

FNR ATTRACT Fellows – the people behind the science: Anne Grünewald

Does Parkinson’s disease originate outside the brain? FNR ATTRACT Fellow leads study suggesting gut bacteria could play a role

Researchers’ Days: What it feels like to have Parkinson’s disease

Spotlight on Young Researchers: Cyrille Thinnes

NCER-PD: Meet Dany, the 100th Parkinson’s study control person

A Centre of Excellence in Research on Parkinson’s disease (NCER-PD)

This site uses cookies. By continuing to use this site, you agree to the use of cookies for analytics purposes. Find out more in our Privacy Statement